COVID-19 UPDATE

At GW Pharmaceuticals, we remain committed to ensuring our patients, healthcare partners and employees are supported during these challenging times. We are actively monitoring our supply chain and taking steps to help ensure continued supply of our products to patients. We will continue to monitor the COVID-19 situation and take steps to ensure that access and assistance for patients and healthcare partners remain consistent. If you wish to discuss more specific details please contact GW Pharmaceuticals via phone on +44 (0) 1223 238170 or via email at medinfo@gwpharm.com.

If you are reporting an Adverse Event and / or a Product Complaint, and you receive a network busy signal (i.e. if all lines are busy or engaged) please continue to try your call throughout the day or, preferably report via the above email address.

Committed to

Making a
Difference.

We believe in the therapeutic potential of cannabinoids, which can bring valuable treatments to seriously ill patients

Find out more

Our commitment in numbers

20.00+

years of experience and heritage

60.00+

Phase 2/3 clinical trials1

135000.00+

patient-years of human safety data from post-marketing sources2

>£1.30bn

invested in R&D activities, facilitates and infrastructure3

100.00+

peer-reviewed publications4

1300.00+

institutions collaborated with as part of research5

Creating a bright future for prescription cannabis-based medicines

Our CEO Justin Gover takes a whistle stop tour through everything GW Pharmaceuticals, from our company vision to how we’ve grown over recent years, our main areas of research and how we foster scientific excellence. But most importantly, how we’ve listened to patients throughout this journey.

Find out more

Our CEO Justin takes a whistle stop tour through everything GW Pharmaceuticals, from our company vision to how we’ve grown over recent years, our main areas of research and how we foster scientific excellence. But most importantly, how we’ve listened to patients throughout this journey.

Find out more

Investing in GW Pharmaceuticals

Find out more about investment

If you are an existing shareholder or potential investor, visit our global corporate site to stay up to date with share price, news and other relevant information.

Visit global corporate site

  1. Data on file (Total number of phase 2-3 clinical trials – >60) – VV-MED-12392.

  2. Data on file (The level of human safety estimated patient-years – >135,000) – VV-MED-12269.

  3. Data on file (Total investment globally – >£1.3bn) – VV-MED-12367.

  4. Data on file (Number of peer reviewed publications – >100) – VV-MED-12883.

  5. Date on file (Total number of institutions collaborated with via our research – >1,300) – VV-MED-12315.